What is Zacks Research’s Estimate for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Zacks Research upped their Q4 2024 earnings per share (EPS) estimates for shares of Exelixis in a research report issued to clients and investors on Monday, December 16th. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of $0.37 per share for the quarter, up from their previous forecast of $0.36. The consensus estimate for Exelixis’ current full-year earnings is $1.69 per share. Zacks Research also issued estimates for Exelixis’ Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.57 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.49 EPS and FY2026 earnings at $2.14 EPS.

Several other research firms also recently issued reports on EXEL. TD Cowen lifted their price target on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. BMO Capital Markets lifted their price objective on shares of Exelixis from $29.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Stifel Nicolaus upped their target price on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. Piper Sandler lifted their price objective on shares of Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Finally, Stephens raised their target price on Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $32.19.

Exelixis Trading Up 0.1 %

Shares of NASDAQ EXEL opened at $33.68 on Thursday. The stock has a fifty day moving average price of $33.36 and a 200 day moving average price of $27.47. The company has a market cap of $9.62 billion, a P/E ratio of 21.59, a P/E/G ratio of 0.89 and a beta of 0.52. Exelixis has a 12-month low of $19.20 and a 12-month high of $36.97.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the previous year, the firm earned $0.10 earnings per share. Exelixis’s revenue for the quarter was up 14.3% on a year-over-year basis.

Insider Buying and Selling at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 1,162 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at $15,666,873. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 339,736 shares of company stock valued at $11,508,610. 2.85% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Exelixis

Institutional investors have recently modified their holdings of the business. V Square Quantitative Management LLC purchased a new stake in Exelixis during the third quarter worth about $30,000. Brooklyn Investment Group purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $42,000. Capital Performance Advisors LLP purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $61,000. Essex Investment Management Co. LLC bought a new stake in shares of Exelixis in the 3rd quarter worth approximately $74,000. Finally, GAMMA Investing LLC lifted its stake in Exelixis by 50.0% in the third quarter. GAMMA Investing LLC now owns 3,010 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 1,004 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.